全文获取类型
收费全文 | 23201篇 |
免费 | 1149篇 |
国内免费 | 170篇 |
专业分类
耳鼻咽喉 | 286篇 |
儿科学 | 418篇 |
妇产科学 | 330篇 |
基础医学 | 3454篇 |
口腔科学 | 361篇 |
临床医学 | 2088篇 |
内科学 | 4373篇 |
皮肤病学 | 728篇 |
神经病学 | 2804篇 |
特种医学 | 1252篇 |
外科学 | 2906篇 |
综合类 | 163篇 |
一般理论 | 6篇 |
预防医学 | 1072篇 |
眼科学 | 612篇 |
药学 | 1820篇 |
中国医学 | 29篇 |
肿瘤学 | 1818篇 |
出版年
2023年 | 86篇 |
2022年 | 137篇 |
2021年 | 292篇 |
2020年 | 241篇 |
2019年 | 294篇 |
2018年 | 390篇 |
2017年 | 315篇 |
2016年 | 436篇 |
2015年 | 491篇 |
2014年 | 692篇 |
2013年 | 868篇 |
2012年 | 1371篇 |
2011年 | 1435篇 |
2010年 | 825篇 |
2009年 | 818篇 |
2008年 | 1508篇 |
2007年 | 1555篇 |
2006年 | 1629篇 |
2005年 | 1649篇 |
2004年 | 1509篇 |
2003年 | 1545篇 |
2002年 | 1449篇 |
2001年 | 309篇 |
2000年 | 265篇 |
1999年 | 346篇 |
1998年 | 344篇 |
1997年 | 285篇 |
1996年 | 230篇 |
1995年 | 185篇 |
1994年 | 209篇 |
1993年 | 156篇 |
1992年 | 121篇 |
1991年 | 156篇 |
1990年 | 135篇 |
1989年 | 118篇 |
1988年 | 121篇 |
1987年 | 75篇 |
1986年 | 88篇 |
1985年 | 98篇 |
1984年 | 97篇 |
1983年 | 86篇 |
1982年 | 87篇 |
1981年 | 98篇 |
1980年 | 76篇 |
1979年 | 74篇 |
1978年 | 60篇 |
1977年 | 68篇 |
1976年 | 69篇 |
1974年 | 61篇 |
1955年 | 49篇 |
排序方式: 共有10000条查询结果,搜索用时 234 毫秒
81.
Martin Krause Wolfgang Fogel Volker Tronnier Sabine Pohle Konstanze H?rtnagel Ute Thyen Jens Volkmann 《Movement disorders》2006,21(12):2255-2257
Pantothenate kinase-associated neurodegeneration (PKAN) is a rare autosomal recessive disorder with onset in childhood and rapid progression. There is no causative and insufficient symptomatic drug therapy. Deep brain stimulation (DBS) of the internal pallidum (GPi) has been reported to improve motor function. Most case reports, however, are limited to short observational periods. The impact of DBS on the progression and life expectancy in PKAN is unknown. We present a 5-year outcome and video documentation of bilateral GPi-DBS of an adolescent patient suffering from genetically defined PKAN. 相似文献
82.
Alexandre Castro-Caldas Paul Delwaide Wolfgang Jost Marcelo Merello Adrian Williams Paolo Lamberti Miguel Aguilar Susanna Del Signore Pierre Cesaro 《Movement disorders》2006,21(4):500-509
Dopamine agonists have been recommended as early treatment for Parkinson's disease (PD), alone or combined with levodopa. Piribedil is a non-ergot selective D(2)/D(3) agonist with alpha(2) antagonist properties shown to be effective in the treatment of PD. This 12-month international, randomized, double-blind trial aimed to assess the efficacy of piribedil 150 mg versus bromocriptine 25 mg, in early combination with levodopa in Stage I to III PD patients. Motor efficacy was assessed using the Unified Parkinson's Disease Rating Scale (UPDRS III, Items 18-31) as improvement from baseline. Response rate was defined as a 30% improvement. Among the 425 randomly assigned patients, 178 were also included in a substudy on cognitive follow-up evaluated by a dysexecutive syndrome oriented battery. A relevant improvement in UPDRS III over the 12-month study duration was observed both in the piribedil and bromocriptine groups (-7.9 +/- 9.7 points from baseline versus -8.0 +/- 9.5; not significant [n.s.]) with a response rate of 58.4% and 55.3% (n.s.), respectively. Piribedil and bromocriptine resulted in similar improvement on all UPDRS III subscores. Piribedil patients required less levodopa dose increase than those on bromocriptine. Cognitive performance remained generally unchanged in both groups, with a significant effect of piribedil limited to the Wisconsin Card Sorting Test. An overall good tolerability of piribedil was observed. Early combination of piribedil 150 mg with levodopa resulted in significant long-term improvement of all motor symptoms in PD patients insufficiently controlled by levodopa alone. Taking into account both efficacy and acceptability in the long-term, piribedil proved in this bromocriptine controlled study to be an effective and safe treatment for PD. 相似文献
83.
Fumiharu Kimura R. Glenn Smith Osvaldo Delbono Okot Nyormoi Toni Schneider Wolfgang Nastainczyk Franz Hofmann Enrico Stefani Stanley H. Appel 《Annals of neurology》1994,35(2):164-171
Sporadic amyotrophic lateral sclerosis is an idiopathic human degenerative disease of spinal cord and brain motor neurons. Prior studies demonstrated that most patients with amyotrophic lateral sclerosis posses immunoglobulins that bind to purified L-type voltage-gated calcium channels, that titers of anti–voltage-gated calcium channel antibodies correlate with disease progression rates, and that amyotrophic lateral sclerosis patient-derived antibodies (ALS IgG) produce electrophysiological changes in the function of voltage-gated calcium channels. Using Western transfer immunoblots and enzyme-linked immunosorbent assays, the calcium ionophore–forming α1 subunig of the voltage-gated calcium channel is now identified as the major voltage-gated calcium channel antigen to which ALS IgG binds. Additionally, the binding of an L-type voltage-gated calcium channel α1 subunit–directed monoclonal antibody, which itself mimics the effects of ALS IgG on skeletal muscle voltage-gated calcium channel currents, is selectively prevented by preaddition of ALS IgG. Voltage-gated calcium channel–binding IgG from patients with Lambert-Eaton myasthenic syndrome appears to be differentiated from ALS IgG by the reactivity of the former to both α1 and β subunits of the calcium channel. These assays provide further evidence linking amyotrophic lateral sclerosis to an autoimmune process, and suggest one means to differentiate immunoglobulins from patients with amyotrophic lateral sclerosis from those of patients with another autoimmune disease expressing calcium channel antibodies. 相似文献
84.
85.
86.
87.
Dieter Ebert Andrea Jaspert Harumi Murata Wolfgang P. Kaschka 《Psychopharmacology》1995,118(2):223-225
The hypothesis was tested that an initial lithium-tricyclic antidepressant (TCA) combination has a better antidepressant effect than standard TCA treatment in non-refractory depression at the beginning of an episode. Twenty bipolar melancholic type depressed inpatients under lithium-TCA treatment were compared with 20 patients with the same diagnosis and TCA-placebo treatment for 5 weeks under double-blind conditions. All patients were male. Initial lithium-TCA treatment reduced depressive symptoms significantly more than antidepressant treatment with TCA and placebo after 5 weeks, but not in weeks 1 or 2. It can be concluded that lithium augmentation of TCA treatment should be started even at the beginning of antidepressant TCA treatment to provide a better treatment response in those patients who will profit from long-term lithium prophylaxis, e.g. bipolar patients with melancholic type depression. 相似文献
88.
The effect of oral appliance therapy on blood pressure in patients with obstructive sleep apnea 总被引:1,自引:1,他引:0
Ryo Otsuka Fernanda Ribeiro de Almeida Alan A. Lowe Wolfgang Linden Frank Ryan 《Sleep & breathing》2006,10(1):29-36
The objective of the study was to investigate the effects of oral appliance (OA) therapy on ambulatory blood pressure in patients
with obstructive sleep apnea (OSA). Eleven OSA patients who received OA therapy were prospectively investigated. Ambulatory
blood pressure was measured for 20 h from 4:00 p.m. to 12:00 noon the next day using an ambulatory blood pressure monitor. The Respiratory Disturbance Index (RDI) was measured
in the pretreatment and posttitration periods. The OA was titrated to reach a therapeutic jaw position over 2 to 8 months,
and posttitration measurements were repeated. At posttitration, the RDI was significantly decreased from a mean (SD) of 24.7
(20.1) to 6.1 (4.5). Significant reductions in diastolic blood pressure (DBP) and mean arterial pressure (MAP) were found
for the 20-h periods, and systolic blood pressure (SBP), DBP, and MAP while asleep. The mean values were 79.5 (5.5) to 74.6
(6.0) for DBP and 95.9 (5.4) to 91.2 (5.9) for MAP, for over a 20-h period, and 118.4 (10.0) to 113.7 (9.1) for SBP, 71.6
(8.0) to 67.2 (7.9) for DBP, and 88.4 (8.0) to 83.9 (7.5) for MAP, while asleep. This study suggests that successful OSA treatment
with an OA may also be beneficial to lower blood pressure in OSA patients, as previously suggested for nasal continuous positive
airway pressure therapy.
This study was conducted in the Division of Orthodontics, The University of British Columbia, Canada 相似文献
89.
Thorsten Gerstner Deike Buesing Elke Longin Claudia Bendl Dieter Wenzel Brigitte Scheid Gisela Goetze Alfons Macke Gerhard Lippert Wolfgang Klostermann Geert Mayer Regine Augspach-Hofmann Sabine Fitzek Carl-Albrecht Haensch Markus Reuland Stephan A Koenig 《Seizure》2006,15(6):443-448
Valproic acid (VPA) is a broad-spectrum antiepileptic drug and is usually well-tolerated. Rare serious complications may occur in some patients, including haemorrhagic pancreatitis, bone marrow suppression, VPA-induced hepatotoxicity and VPA-induced encephalopathy. The typical signs of VPA-induced encephalopathy are impaired consciousness, sometimes marked EEG background slowing, increased seizure frequency, with or without hyperammonemia. There is still no proof of causative effect of VPA in patients with encephalopathy, but only of an association with an assumed causal relation. We report 19 patients with VPA-associated encephalopathy in Germany from the years 1994 to 2003, none of whom had been published previously. 相似文献
90.
Betahistine is a structural analogue of histamine that is prescribed for the treatment of vestibular disorders such as Ménière's disease and the symptomatic treatment of vertigo. It is estimated from sales information that >130 million patients have been exposed to the drug since its registration in 1968. In this review we analyse the safety profile of betahistine based on data obtained during >35 years of worldwide postmarketing surveillance. Until 31 December 2005, 554 adverse drug reaction (ADR) reports with 994 individual signs and symptoms were received by the marketing authorisation holder from worldwide sources and were reviewed and evaluated. Signs and symptoms of cutaneous hypersensitivity reactions during betahistine therapy were the most frequently reported complaints. They consisted of usually mild and self-limiting rash, pruritus and urticaria, and all symptoms were reversible after drug discontinuation. Betahistine was reported to be involved in one anaphylactoid reaction and one case of Stevens-Johnson syndrome. Anaphylactic reactions with fatal outcome were not reported. The reports that describe gastrointestinal complaints mostly concern nausea and vomiting or unspecific abdominal pain. These were typically non-serious complaints. Hepatobiliary involvement was reported 25 times, including increases in alkaline phosphatase, gamma-glutamyltransferase, and alanine and aspartate aminotransferase levels. None of the patients concerned developed severe liver failure or died. ADRs related to the nervous system predominantly reveal heterogeneous events that are not suggestive of a specific adverse reaction profile for betahistine. A clinical intolerance to betahistine that gave rise to asthma or bronchospasm was only reported in eight ADRs. A total of three cases of neoplasm have been reported. One case concerned a male patient of unknown age who experienced weight loss, insomnia, impatience and irritability soon after the start of betahistine therapy. An undiagnosed phaeochromocytoma was suspected. The remaining two cases were assessed as being unrelated to betahistine by the reporter. Finally, four deaths have been reported during the course of postmarketing surveillance for betahistine. The reporter assessed the causal relationship to betahistine in two as unrelated, in one as unlikely and the other as unassessable. In summary, clinical and postmarketing studies have revealed a good safety profile of betahistine that was confirmed by the safety surveillance data presented. 相似文献